Chinese Vaccine for COVID Reduces Mortality Risk More Than Pfizer’s Drug, According to a New Study

Chinese Vaccine for COVID Reduces Mortality Risk More Than Pfizer’s Drug, According to a New Study
SHARE

While many experts add a lot of faith in the COVID vaccine developed by Pfizer/BioNTech, a Chinese vaccine for the coronavirus is even more efficient, according to preliminary results of a study that was recently published in Uruguay.
CoronaVac, or the Sinovac COVID-19 vaccine, is the drug in question that’s developed by the Chinese company Sinovac Biotech. Queencitizen.ca brings the great news of CoronaVac’s high efficiency,

5,360 people who tested positive for COVID were immunized with CoronaVac

“Reduction of deaths due to COVID-19 for more than 14 days after administration of the second dose of the vaccine, 97% for coronavirus and 80% for Pfizer”, indicates the study conducted by the Uruguayan Ministry of Health.
The study has shown that 5,360 people tested positive for COVID and were immunized with the CoronaVac vaccine. Nineteen of these people needed hospitalization in intensive care units, and six patients died.
According to worldometers.info, a number of over 3.5 million people have died worldwide as a result of illness with COVID-19 since the start of the pandemic. The total number of infections exceeds 169 million people, while about 151 million patients had been recovered.
Although the US remains the hardest-hit country by the COVID pandemic, the number of daily infections and deaths due to the coronavirus had been significantly gone down in the last months.


SHARE

Share this post

Post Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.